Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,665,552 — The development of a protective and/or therapeutic HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, a cleverly engineered entry machinery that features an extraordinary assortment of immune-evasion tactics, includin…
T. Jake Liang · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $726,910 — HCV dependencies on the host machinery are both intricate and extensive. Each of these host dependencies is a potential therapeutic target. Previous efforts have been successful in discovering important steps in HCV replication, yet many fundamental processes in the viral life cycle remain uncharact…
CHRISTOPHER P. HILL · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2021 · $400,365 — ABSTRACT The success of antiretroviral therapy (ART) has transformed the HIV/AIDS pandemic into a life-long chronic disease, yet major challenges remain as a growing population of ~35 million patients living with HIV continues to face significant health challenges. These include side-effects and tox…
Mathias Lichterfeld · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2021 · $223,467 — Project Summary/Abstract, Immune Control (Project 4) Finding a cure for HIV-1 infection is of particular importance for the growing number of HIV-1-infected infants, children and teenagers who will have to take lifelong antiretroviral therapy if curative treatment options will not be available. Rece…
GARRY P NOLAN · STANFORD UNIVERSITY · 2021 · $293,948 — PROJECT SUMMARY New technologies such as mass cytometry have greatly expanded our ability to deepen our understanding of the complexity of lymphocytes and related populations. The Stanford CCHI group has been particularly attuned to the potential in following the lead of the Nolan lab in exploiting …
Matthew Adrian Coleman · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · 2021 · $383,595 — ABSTRACT Throughout the world Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen. In countries with poor sanitary conditions ocular infections with Ct can result in trachoma, the most frequent cause of preventable blindness worldwide. Based on protection and serolo…
CATHERINE MARY O'CONNELL · UNIV OF NORTH CAROLINA CHAPEL HILL · 2021 · $117,278 — In a subset of Chlamydia trachomatis-infected women, the infection escapes immune control and ascends to the upper reproductive tract. There is a fundamental gap in understanding how pathways activated by chlamydial infection lead to immune pathology and reproductive morbidity in women. Its continue…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $3,622,426 — Administrative Core The IPCAVD Administrative Core will serve to coordinate all scientific and administrative activities of the Duke IPCAVD, ensuring that the Projects and Cores function well together. A primary activity of the Core will be monitoring IPCAVD progress relative to milestones and measu…
Thomas Denny · DUKE UNIVERSITY · 2021 · $3,489,292 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
SAM ON HO · MOLECULAR EXPRESS, INC. · 2021 · $299,994 — Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery …
CHINTHALAPALLY RAO · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2021 · $845,841 — It has been shown that the extracellular domain of human anti-Müllerian hormone receptor type II (AMHR2-ED) is a prototypic ‘retired’ tissue-specific protein that may serve as a vaccine target for primary immunoprevention of epithelial ovarian cancer. AMHR2 is a serine/threonine kinase receptor homo…
Hiten D Madhani · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $620,877 — Objective: We propose to construct and distribute a series of SARS-CoV-2-derived molecular clones using powerful genome assembly and rapid CRISPR-based manipulation methods available in the yeast Saccharomyces cerevisiae. We will develop and apply methods to mutate and tag each of the 18 viral prote…
HANA M EL SAHLY · BAYLOR COLLEGE OF MEDICINE · 2020 · $5,921,655 — ABSTRACT This supplement request is for a Phase 3, randomized, stratified, observer-blind, placebo- controlled study to evaluate the efficacy, safety and immunogenicity, of mRNA-1273 vaccine compared to placebo in adults 18 years of age and older who have no known history of SARS- CoV-2 infection bu…
Siyuan Ding · WASHINGTON UNIVERSITY · 2020 · $393,125 — Project Summary Rotaviruses (RVs) are a medically important human pathogen and the predominant cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children worldwide. RVs are also a great model to interrogate the antiviral responses at the host mucosal surfaces. Our overall…
BRUNO DE BEZERRIL ANDRADE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2020 · $972,111 — PROJECT SUMMARY Recent studies from our group have reported a peripheral blood correlate of risk (COR) transcriptional signature that identified individuals with incipient (asymptomatic) TB who progressed to active (symptomatic) TB disease within 12 months. We have also identified human genetic poly…
Patricia DEVAUX · MAYO CLINIC ROCHESTER · 2020 · $318,000 — Abstract. The recent advances in induced pluripotent stem cells (iPSCs) and gene therapy tools have opened up a new avenue to study and treat diseases, particularly of disorders with defective bone marrow. Bone marrow failure syndromes (BMFS) are characterized by reduced blood cells due to a dysfunc…
Toni Darville · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $795,093 — DESCRIPTION (provided by applicant): Chlamydia trachomatis infection is the leading cause of infertility and ectopic pregnancy in women. Infection is often asymptomatic, leading to lack of detection, increased risk for disease and delay in treatment. Although antibiotic therapy eliminates infec…
Dipak Kumar Raj · BROWN UNIVERSITY · 2020 · $400,000 — Project Summary The overall aim of this application is to advance PfCDPK5 and PfGARP as vaccine candidates for falciparum malaria. P.falciparum malaria affects almost one-half of the world's population and causes more than 500,000 deaths annually. Young children in malaria endemic areas of Africa h…
Kimberly D. Klonowski · UNIVERSITY OF GEORGIA · 2020 · $188,750 — Abstract Identifying the mechanisms that regulate CD8 T cell responses is critical for improving anti-viral and anti-tumor vaccine efficacy and is currently an area of intense investigation due to the profound implications for improving human health. The goal of this application is to determine the …
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2020 · $560,736 — This application is to extend a MERIT award to study RNA synthesis in minus-strand RNA viruses. Nonsegmented negative-sense (NNS) RNA viruses include some of the most significant human pathogens that are an ongoing threat to US public health. For measles, mumps and rabies there are licensed vaccines…